Cargando…

Histology Matters: Individualizing Treatment in Non-Small Cell Lung Cancer

This editorial discusses the role of histology in non-small cell lung cancer treatment.

Detalles Bibliográficos
Autor principal:	Neal, Joel W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2010
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227884/ https://www.ncbi.nlm.nih.gov/pubmed/20086166 http://dx.doi.org/10.1634/theoncologist.2009-0306

Ejemplares similares

Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
por: Patel, Shruti R., et al.
Publicado: (2023)

Cisplatin or carboplatin for advanced non-small cell lung cancer: does it really matter?
por: Kesireddy, Meghana, et al.
Publicado: (2021)

Dose matters for stereotactic body radiotherapy for early stage non-small cell lung cancer
por: Okoye, Christian C., et al.
Publicado: (2020)

Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer
por: Mamdani, Hirva, et al.
Publicado: (2017)

Treatment strategy of EGFR-mutated non-small cell lung cancer
por: Tanaka, Fumihiro, et al.
Publicado: (2022)

Individualization of treatment in non-small cell lung cancer
por: van Zandwijk, Nico
Publicado: (2009)

Diagnosis and treatment of non-small cell lung cancer: current advances and challenges
por: Diebels, Ian, et al.
Publicado: (2022)

Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision Medicine
por: Pons-Tostivint, Elvire, et al.
Publicado: (2022)

The quality of systematic reviews on the treatment of stage I non-small cell lung cancer for individualized decision-making: improved but further refinements are needed
por: Sun, Yajia, et al.
Publicado: (2022)

Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer
por: Lu, Ying-Qiang, et al.
Publicado: (2017)

Vistas in Non-Small Cell Lung Cancer (NSCLC) Treatment: of Kinome and Signaling Networks
por: Stravopodis, Dimitrios J., et al.
Publicado: (2023)

Surgical treatment of small-sized non-small cell lung cancer—a dilemma for surgeons
por: Kodama, Ken, et al.
Publicado: (2020)

Induction treatment in operable non-small cell lung cancer: the immune oncology era unfolds
por: Walker, Paul R.
Publicado: (2023)

Evolution in the management of non-small cell lung cancer in Brazil
por: Fernandes, Caio Júlio Cesar dos Santos
Publicado: (2017)

Realities of KRAS-mutated non-small cell lung cancer
por: Min, Young Joo
Publicado: (2017)

Immunotherapy in non-small cell lung cancer: advancements and challenges
por: Zhou, Fei, et al.
Publicado: (2021)

Resectable non-small cell lung cancer: an evolving landscape
por: Loh, Jerold, et al.
Publicado: (2022)

Histological transformation from non-small cell to small cell lung carcinoma
por: Haruta(Inoue), Yuki, et al.
Publicado: (2016)

The not so small role of adjuvant chemotherapy in resected non-small cell lung cancer
por: Almquist, Daniel R., et al.
Publicado: (2021)

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
por: Nguyen, Kim-Son H, et al.
Publicado: (2012)

Histologic Changes in Non–Small Cell Lung Cancer under Various Treatments: A Comparison of Histology and Mutation Status in Serial Samples
por: Woo, Chang Gok, et al.
Publicado: (2022)

Subtyping non-small cell lung cancer by histology-guided spatial metabolomics
por: Neumann, Judith Martha, et al.
Publicado: (2021)

Functions of metabolic enzymes in the development of non‐small cell lung cancer
por: Zhao, Gang
Publicado: (2019)

Immunotherapy in non‐small cell lung cancer: The past, the present, and the future
por: Lu, Meng, et al.
Publicado: (2019)

Biomarkers for Non-Small Cell Lung Cancer: From the Bench to the Bedside
por: de Mello, Ramon Andrade, et al.
Publicado: (2020)

Identifying successful biomarkers for patients with non-small-cell lung cancer
por: Friedlaender, Alex, et al.
Publicado: (2019)

Immunotherapy as a targeted therapy in non-small cell lung cancer
por: Rocco, Danilo, et al.
Publicado: (2019)

Surgery for Non-Small Cell Lung Cancer in the Personalized Therapy Era
por: Chiappetta, Marco, et al.
Publicado: (2023)

Relationship of driver oncogenes to long term pemetrexed response in non-small cell lung cancer
por: Liang, Ying, et al.
Publicado: (2014)

From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
por: Pirker, Robert, et al.
Publicado: (2019)

Stereotactic body radiation therapy for metastatic non-small cell lung cancer: a versatile treatment, repurposed
por: Shen, James L., et al.
Publicado: (2022)

Biomarkers predictive value in early stage non-small cell lung cancer
por: Malapelle, Umberto, et al.
Publicado: (2020)

Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods
por: Zarogoulidis, Paul, et al.
Publicado: (2019)

Neoadjuvant immunotherapy for patients with non-small cell lung cancer—current evidence
por: Cao, Christopher, et al.
Publicado: (2020)

Neoadjuvant immunotherapy in resectable non-small cell lung cancer at a checkpoint
por: Faltermeier, Claire M., et al.
Publicado: (2021)

Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Critical points in the management of EGFR-mutated non-small cell lung cancer
por: Casaluce, Francesca, et al.
Publicado: (2022)

TTF-1 and immune checkpoint therapy in non-small cell lung cancer
por: Gumbleton, Matthew, et al.
Publicado: (2023)

Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases
por: Jin, Cai-Bao, et al.
Publicado: (2021)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_aino2h9u0a29qm30382hk1e2g2